Coming Soon: Permanent J Code ( J2777) for Vabysmo – 8/30/22

[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_column type=”4_4″ _builder_version=”4.19.4″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_code _builder_version=”4.19.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”et_body_layout” sticky_enabled=”0″] /* OUTLOOK-SPECIFIC STYLES */ li { text-indent: -1em; padding: 0; margin: 0; /* line-height: 1.2; Remove after testing */ } ul, ol { padding: 0; margin: 0 0 0 40px; } p { margin: 0; padding: 0; margin-bottom: 0; } Coming Soon: A Permanent J-code (J2777) for VABYSMO®

Coming Soon: 

A Permanent J-code (J2777) for VABYSMO®

effective for services beginning October 1, 2022 

A permanent J-code will go into effect for dates of service beginning October 1, 2022.

J2777: Injection, faricimab-svoa, 0.1 mg

Please ensure your systems are updated to accept J2777 for VABYSMO for services starting October 1, 2022


  • 50242-0096-01: VABYSMO (6 mg/0.05 mL) single-dose vial with sterile 5-micron blunt transfer filter needle (18-gauge × 1.5 inch)

VABYSMO is the first and only dual-pathway inhibitor that targets 2 drivers of Neovascular (Wet)

Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)—Ang-2 and


For more information about VABYSMO coding and billing:


Call (833) EYE-GENE/(833) 393-4363

Monday-Friday, 9 a.m.- 8 p.m. ET


VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).


Important Safety Information



VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. 


Warnings and Precautions

  • Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management.
  • Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.
  • There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition. 


Adverse Reactions

The most common adverse reaction (≥5%) reported in patients receiving VABYSMO was conjunctival hemorrhage (7%).


You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.


Please see additional Important Safety Information in the full VABYSMO Prescribing Information.

Ang-2=angiopoietin-2; FDA=US Food and Drug Administration; VEGF=vascular endothelial growth factor.


References: 1. VABYSMO. Package insert. Genentech, Inc; 2022. 2. BEOVU. Package insert. Novartis Pharmaceuticals Corporation; 2022.3. EYLEA. Package insert. Regeneron Pharmaceuticals, Inc; 2021. 4. LUCENTIS. Package insert. Genentech, Inc; 2018. 5. SUSVIMO. Package insert. Genentech, Inc; 2022.

VABYSMO is a registered trademark of Genentech, Inc., and the VABYSMO logo is a trademark of Genentech, Inc.


©2022 Genentech USA, Inc.      So. San Francisco, CA     All rights reserved.